To Compare Effectiveness and Safety of Teneligliptin vs Glimepiride in Patients with Type 2 Diabetes Mellitus
DOI:
https://doi.org/10.48165/h2ktab59Keywords:
Teneligliptin, Glimepiride, Type 2 Diabetes MellitusAbstract
Background: To determine the efficacy of Teneligliptin [DPP-4 inhibitor] vs Glimepiride [sulfonylurea] in patients with type 2 diabetes mellitus. Materials and Methods: Patients with inadequate glycemic control with maximum tolerable dose of metformin were randomly divided into 2 groups (Group A & Group B). Group A was started on Teneligliptin and Group B on Glimepiride. The patients were assessed for weight, fasting plasma glucose (FPG), post parandial glucose (PPG), HbA1c and Lipid Profile. The patients were followed up in OPD for 3 months. The difference in all the mentioned parameters were used to determine the efficacy of Teneligliptin V/S Glimepiride. Result: There were more males as compared to females. Most of the subjects in both the groups were having age >50 years. Mean age in group A and B was 58.72±12.78 and 59.31±13.06 years individually. Family history of diabetes was discovered in 38.69% and 45.61% of the subjects in group A and B individually. The duration of diabetes was 42.11% and 47.37% of the subjects in group A and B since 5-10 years. Hypertension and cardiovascular disease were found in 14.04%, 5.26% and 19.30%, 3.51% of the subjects in group A and B. Lipid profile viz. Cholesterol, HDL, LDL and VLDL was similar among both the groups as p>0.05. Conclusion: In the current research, Glimepiride as well as Teneligliptin were very much endured when added to Metformin. Patients on Metformin+Teneligliptin displayed better command in control of glycemic profile as well as lipid profile. Thus, Teneligliptin is the better choice as an add-on medication to Metformin in type 2 diabetes patients.
References
1. Sami W, Ansari T, Butt NS, Hamid MRA. Effect of diet on type 2 diabetes mellitus: A review. Int J Health Sci (Qassim). 2017;11(2):65–71.
2. American Diabetes Association. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes 2019. Diabetes Care. 2019;42(1):90–102. Available from: https://doi.org/10.2337/dc19-s009.
3. Kim HJ, Kim YS, Lee CB, Choi MG, Chang HJ, Kim SK. Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: A 12-Week Interim Report. Diabetes Ther. 2019;10(4):1271–1282. Available from: https://doi.org/ 10.1007/s13300-019-0628-0.
4. Ghosh S, Trivedi S, Sanyal D, Modi KD, Kharb S. Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study). Diabetes Metab Syndr Obes. 2016;9:347–353. Available from: https://dx.doi.org/10. 2147/DMSO.S121770.
5. Maladkar M, Sankar S, Kamat K. Teneligliptin: Heralding Change in Type 2 Diabetes. J Diabetes Mellit. 2016;6(2):113– 131.
6. Nishanth T, Maheshwari CU, Lakshmi RS, Sri D, Goud P, Tabassum K. A study to compare efficacy of Metformin Glimepiride versus Metformin-Teneligliptin in type II diabetic patients. Int J Pharm Sci Res. 2018;9(12):5258–5264.
7. Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, Cho YM. Differ ences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia. 2013;56(4):696–708. Avail able from: https://doi.org/10.1007/s00125-012-2827-3.
8. Gadge PV, Gadge RP, Paralkar ND. Patients characteristics associated with better glycemic response to teneligliptin and metformin therapy in type 2 diabetes: a retrospective study. IJAM. 2018;5(2):424–428. Available from: https://dx.doi.org/ 10.18203/2349-3933.ijam20181082.
9. Hans N. The Efficacy and Safety of Teneligliptin and Metformin versus Glimepiride and Metformin in Patients of Type-2 Diabetes Mellitus Uncontrolled with Monotherapy. J Diabetes Metab. 2019;10(7):829.
10. Nabeno M, Akahoshi F, Kishida H, Miyaguchi I, Tanaka Y, Ishii S. A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site. Biochem Biophys Res Commun. 2013;434(2):191– 196. Available from: https://doi.org/10.1016/j.bbrc.2013.03. 010
